Antifungal activity of propolis extract against yeasts isolated from vaginal exudates

Journal of Alternative and Complementary Medicine

Volumn 16, Issue 3, 2010, Pages 285-290

  Dalben Dota, Kelen F ^a   Faria, Maria G I ^a   Bruschi, Marcos L ^a   Pelloso, Sandra M ^a   Lopes Consolaro, Marcia E ^a   Svidzinski, Terezinha I E ^a  

^a STATE UNIVERSITY OF MARINGÁ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

FLAVONOID; NYSTATIN; PROPOLIS;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA ALBICANS; CONTROLLED STUDY; FEMALE; FUNGAL STRAIN; FUNGUS ISOLATION; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; VAGINA CANDIDIASIS;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, VULVOVAGINAL; EXUDATES AND TRANSUDATES; FEMALE; HUMANS; MICROBIAL SENSITIVITY TESTS; NYSTATIN; PROPOLIS;

EID: 77649293807     PISSN: 10755535     EISSN: None     Source Type: Journal    
DOI: 10.1089/acm.2009.0281     Document Type: Article

References (28)

1. Geva A, Bornstein J, Dan M, et al. The VI-SENSE-vaginal discharge self-test to facilitate management of vaginal symptoms. Am J Obstet Gynecol 2006;195:1351-1356.
2. Reese RE, Betts RF. Antibiotic use. In: Reese RE, Betts RF, eds. A Practical Approach to Infectious Disease. 3rd ed. Boston: Little, Brown and Company, 1991:821.
3. Sobel JD. Vulvovaginal candidosis. Lancet 2007;369:1961-1971.
4. Ferraza MHSH, Maluf MLF, Consolaro MEL, et al. Characterization of yeasts isolated from the vagina and their association with vulvovaginal candidiasis in two cities of the South of Brazil. Rev Bras Ginecol Obstet 2005;27: 58-63.
5. Consolaro MEL, Albertoni TA, Yoshida CS, et al. Correlation of Candida species and symptoms among patients with vulvovaginal candidiasis in Maringá, Paraná, Brazil. Rev Iberoam Micol 2004;21:202-205.
6. Corsello S, Spinillo A, Osnengo G, et al. An epidemiological survey of vulvovaginal candidiasis in Italy. Eur J Obstet Gynecol Reprod Biol 2003;110:66-72.
7. Ghannoum MA, Rice LB. Antifungal agents: Mode of actions, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999;12:501-517.
8. Consolaro MEL, Albertoni TA, Svidzinski AE, et al. Vulvovaginal candidiasis is associated with the production of germ tubes by Candida albicans. Mycopat 2005;159:501-507.
9. Dota KFD, Shinobu CS, Patussi EV, et al. Susceptibility to vaginal yeast in most used antifungal in Maringá, Paraná, Brazil Acta Bioquim Clín Latinoam 2008;42:561-566.
10. Burdock GA. Review of the biological properties and toxicity of bee propolis (Propolis). Food Chem Toxicol 1998;36: 347-363.
11. Imhof M, Lipovac M, Kurz C, et al. Própolis solution for the treatment of chronic vaginitis. Int J Gynecol Obstet 2005;89: 127-132.
12. Oliveira ACP, Shinobu CS, Longhini R, et al. Antifungal activity of própolis extract against yeasts isolated from onychomycosis lesions. Mem Inst Oswaldo Cruz 2006; 101:493-497.
13. Larone DH. Medically Important Fungi. A Guide to Identification. 3rd ed. Washington: ASM Press, 2005.
14. Sugita T, Kurosaka S, Yajitate M, et al. Extracellular proteinase and phospholipase activity of three genotypic strains of a human pathogenic yeast, Candida albicans. Microbiol Immunol 2002;46:881-883.
15. Bruschi ML, Martins CHG, Casemiro LA, et al. Preparation and antimicrobial activity of gelatin microparticles containing propolis against oral pathogens. Drug Dev Ind Pharm 2006;32:229-238.
16. Brasileira Pharmacopoeia. 4th ed. São Paulo: Atheneu, 1988.
17. Bruschi ML, Klein T, Lopes RS, et al. Contribution to the quality control protocol of propolis and its extracts. Rev Ciênc Farm 2002;23:289-306.
18. Clinical Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing for Yeasts: Approved Standard, M27-A2. Wayne, PA: Clinical Laboratory Standards Institute, 2002.
19. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing for Yeasts: Approved Standard, M27-A. Wayne, PA: National Committee for Clinical Laboratory Standards, 1997.
20. Bruschi ML, Franco SL, Gremião MP. Application of an HPLC method for analysis of propolis extract. J Liq Chromat Rel Technol 2003;26:2381-2391.
21. Bruschi ML, Cardoso MLC, Luchesi MB, Gremião MP. Gelatin microparticles containing propolis obtained by spraydrying technique: Preparation and characterization. Int J Pharm 2003;264:45-55.
22. Bruschi ML, Jones DS, Panzeri H, et al. Semisolid systems containing propolis for the treatment of periodontal disease: In vitro release kinetics, syringeability, rheological, textural, and mucoadhesive properties. J Pharm Sci 2007;96:2074-2089.
23. Bankova VS, Dyulgerov A, Popov SS, et al. Propolis produced in Bulgaria and Mongolia: Phenolic compounds and plant origin. Apidologie 1992;23:79-85.
24. Sojakova M, Liptajova D, Borovsky M, Subik J. Fluconazole and itraconazole susceptibility of vaginal yeast isolates from Slovakia. Mycopathologia 2004;157:163-169.
25. Lynch ME, Sobel JD, Fidel PL Jr. Role of fungal drug resistance in the pathogenesis of recurrent vulvovaginal candidiasis. J Med Vet Mycol 2000;34:337-339.
26. Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet 2002;359:1135-1144.
27. Nyirjesy P, Seeney SM, Grody MHT, et al. Chronic fungal vaginitis: The value of cultures. Am J Obstet Gynecol 1995;173:820-823.
28. Azevedo RVP, Komesu MC, Candido RC, et al. Candida sp in the oral cavity with and without lesions: Maximal inhibitory dilution of própolis and periogard. Rev Microbiol 1999;30:335-341.